We have a treatment for COPD that can improve symptoms, exercise capacity, and quality of life. We also have a system that makes it difficult for many patients to get it.
Kivo Health just raised $10 million to expand a different approach: respiratory therapist-led pulmonary rehabilitation delivered virtually at home.
I’ve written before about pulmonary rehab’s underuse. In this article, I’ll explain what Kivo does, why pulmonary rehab matters, and what its model could mean for our patients and practices.
The Deets: Kivo Health
Kivo announced its $10 million in Series A funding on October 27, 2026, bringing its total funding to more than $16 million. This round will support health-plan partnerships, clinical expansion, and development of its AI platform. It also plans to eventually expand beyond COPD.
Here’s how the virtual pulmonary rehab works:
Patients receive a tablet, oxygen monitor, and exercise bands.
They meet individually with a respiratory therapist to develop a care plan, then join small-group video sessions twice a week for nine weeks.
The sessions combine exercise, breathing techniques, and COPD education.
Kivo provides cellular connectivity and offers support after the program.
A virtual option could help patients who cannot regularly travel to a center. It may also give practices another referral destination when local programs have limited capacity (which is common). Whether it works for an individual patient depends on clinical stability, safety, preferences, coverage, and the support available at home.
The company describes its platform as AI-supported, but the public descriptions I reviewed don’t establish how much the AI itself contributes to clinical outcomes. I’d separate the value of therapist-led rehab from claims about the technology supporting it.
Why Pulmonary Rehab Is Critical
Pulmonary rehabilitation combines exercise training, education, and support for behavior change to help people with chronic lung disease improve their function and manage symptoms.
The American Thoracic Society strongly recommends pulmonary rehabilitation for adults with stable COPD and after hospitalization for an exacerbation. For adults with stable chronic respiratory disease, it also recommends offering a choice between center-based rehab and telerehabilitation.
Yet participation remains low. In a study of more than 223,000 Medicare beneficiaries hospitalized with COPD, only 2.7% received pulmonary rehab within a year of discharge. That study used older data, so the figure shouldn’t be treated as a current national rate, but it illustrates the size of the historical gap.
Pulmonary rehab requires more than writing a referral. Patients need an available program, a way to get there, insurance coverage, and enough support to keep showing up. For someone who gets short of breath walking across a room, traveling to a facility multiple times a week can be a substantial barrier.
Some patients never receive a referral. Others face limited local capacity, transportation challenges, competing appointments, or costs. A referral is only the first step and it doesn’t guarantee that a patient will enroll or complete a program.
Dashevsky’s Dissection
I’m a strong supporter of pulmonary rehab, and even virtual pulmonary rehab. The data supporting its efficacy is clear—we just need better uptake.
For patients, virtual rehab could make a meaningful difference for people who struggle to travel to a program. But care still has to be affordable and practical at home. In a study of patients referred to Kivo, out-of-network coverage was the most common reported reason among patients who could be contacted and gave a reason for declining. A virtual option won’t help much if a patient can’t use their insurance to access it.
On the pulmonologist side, I like the idea of having another rehab option for patients who can’t get to a center. We still need to consider clinical stability, oxygen requirements, fall risk, and patient preference—and know how the rehab team will communicate with us if symptoms worsen.
The early Kivo data are encouraging: in a retrospective study of 167 patients, symptoms and functional measures improved after the program. But there was no comparison group, and participants were selected for virtual care. We can’t assume every patient will benefit equally or that Kivo’s model is equivalent to center-based rehab.
For health systems, the virtual pulmonary rehab option should be attractive as it may save substantial costs. More patients completing rehab could mean fewer costly hospitalizations, but that outcome needs to be demonstrated for this model. Kivo cites an actuarial estimate of $8,245 in potential annual savings per member.
I’ve previously covered a respiratory therapist–led home-visit program associated with fewer COPD readmissions. It was a different intervention, but it points to the same opportunity: supporting patients after they leave the hospital. For Kivo, I’d want to see whether more patients enroll and complete rehab, how their outcomes compare with other options, and whether any savings outweigh the cost of delivering the program.
In summary, Kivo’s funding reflects a growing interest in delivering pulmonary rehabilitation at home. Its clinician-led model could remove travel barriers for some patients, and early observational data are encouraging. The next test is whether virtual programs can turn more referrals into completed rehab, deliver safe and meaningful outcomes across patient populations, and fit into pulmonary practice without adding another disconnected workflow.




